Cronos Group Inc vs Humana Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 39.4× Cronos Group Inc's market cap, and Humana Inc pays a 0.91% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Humana Inc for 51 Days on average.
| CRON | HUM | |
|---|---|---|
Market Cap | $1.18B | $46.49B |
Volume | 968,037 | 2,567,704 |
Sector | Health | Health |
52-Week High | $3.55 | $409.85 |
52-Week Low | $2.30 | $163.67 |
Typical Hold Time | 22 Days | 51 Days |
Enterprise Value | $387.62M | $53.84B |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with 58% YoY revenue growth, and maintains a robust balance sheet with $827 million in cash and no debt. Recent investor day highlighted expansion in Canada and international markets.
Outlook is mixed; profitability improved with net income margin turning positive in 2026 forecasts, but high EV/EBITDA of 43 suggests premium valuation. Risks include execution of growth plans and cannabis sector volatility. Analyst consensus is cautious with 60% hold ratings.
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →